Recordati S.p.A.
REC.MIDrugs in Pipeline
9
Phase 3 Programs
3
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Mercaptamine
Cystinosis
Methadone
Pain Related to Cancer
Silodosin
Benign Prostatic Hyperplasia
Lercanidipine
Essential Hypertension
Rec 0/0438 1 mg or Rec 0/0438 2 mg
Neurogenic Detrusor Overactivity
Pasireotide Diaspartate
Post-Bariatric Hypoglycemia
LCI699
Cushing Syndrome
Udonitrectag
Neurotrophic Keratitis
osilodrostat
Cushing's Syndrome
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Mercaptamine | Phase 3 | Cystinosis | - | - |
Methadone | Phase 3 | Pain Related to Cancer | - | - |
Silodosin | Phase 3 | Benign Prostatic Hyperplasia | - | - |
Lercanidipine | Phase 2 | Essential Hypertension | - | - |
Rec 0/0438 1 mg or Rec 0/0438 2 mg | Phase 2 | Neurogenic Detrusor Overactivity | - | - |
Pasireotide Diaspartate | Phase 2 | Post-Bariatric Hypoglycemia | - | - |
LCI699 | Phase 2 | Cushing Syndrome | - | - |
Udonitrectag | Phase 2 | Neurotrophic Keratitis | - | - |
osilodrostat | Phase 2 | Cushing's Syndrome | - | - |
Frequently asked questions
What is in Recordati S.p.A.'s drug pipeline?→
CatalystAlert tracks 9 drug candidates in Recordati S.p.A.'s (REC.MI) pipeline across Phase 3, Phase 2. Its lead program is Mercaptamine (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Recordati S.p.A.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Recordati S.p.A. (REC.MI) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track REC.MI biotech catalysts?→
Add REC.MI to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Recordati S.p.A.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.